Literature DB >> 31786354

Utilization of a fattigation platform gelatin-oleic acid sodium salt conjugate as a novel solubilizing adjuvant for poorly water-soluble drugs via self-assembly and nanonization.

Dayoung Kim1, Chulhun Park1, Nileshkumar M Meghani1, Thao T D Tran2, Phuong H L Tran3, Jun-Bom Park4, Beom-Jin Lee5.   

Abstract

Solubilizing adjuvants are commonly used to dissolve insoluble drugs by simply adding in a formulation. In this study, gelatin and oleic acid sodium salt (OAS), a generally recognized as safe-listed material were chosen and conjugated to develop a natural solubilizing adjuvant using the fattigation platform technology to enhance solubility and dissolution rate of poorly water-soluble drugs according to self-assembly and nanonization principle when simply mixed with poorly water-soluble drugs. We synthesized the gelatin and OAS conjugates (GOC) at three different ratios (1:1, 1:3, 1:5; GOC 1, GOC 2, and GOC 3, respectively) via the 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide/N-hydroxysuccinimide reaction using a spray dryer. This amphiphilic micronized GOC was self-assembled into nanoparticles. The synthesis of new amphiphilic conjugates was identified through Fourier transform-infrared (FT-IR) spectroscopy. The powder properties of the GOCs, such as angle of repose, bulk density, and tapped density were varied with the oleic acid bonding ratio. Then, GOCs were utilized to investigate the enhanced solubility and release rate of various poorly water-soluble drugs such as cilostazol (CSZ), coenzyme Q10, ticagrelor, telmisartan, aprepitant and itraconazole as model drugs. Based on the solubility studies by concentration and type of GOCs, 3% GOC 2 was selected. When this GOC was mixed with these model drugs by the physical mixing, wetting and hot melting methoods, the solubility was highly enhanced compared to the pure control drug, ranging from 20 to 150,000 times. In case of CSZ, all formulations were significantly improved release rate compared to the of CSZ alone and the reference tablet, cilostan® (Korea United Pharm) in simulated intestinal fluid containing 0.2% sodium lauryl sulfate. Differential scanning calorimetry and powder X-ray diffraction were conducted to confirm the crystal polymorphic structure of CSZ, and as a result they changed to diminutive peak intensity compared to CSZ alone. Field-emission scanning electron microscopy indicated that GOC was round with a reduced size of about 100 nm. The reduction of drug particles via nanonization and self-assembly of amphiphilic GOC in an aqueous media could be a key factor to improve poor water solubility by providing a favorable dispersion of drug molecules in an amphiphilic network.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Fattigation platform; Gelatin-oleic acid conjugate (GOC); Initial solubility; Nanonization; Poorly water-soluble drugs; Self-assembly; Solubilizing adjuvant

Mesh:

Substances:

Year:  2019        PMID: 31786354     DOI: 10.1016/j.ijpharm.2019.118892

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  3 in total

1.  Hydroxyl Group-Targeted Conjugate and Its Self-Assembled Nanoparticle of Peptide Drug: Effect of Degree of Saturation of Fatty Acids and Modification of Physicochemical Properties.

Authors:  Jisoo Park; Hai V Ngo; Hyo-Eon Jin; Kye Wan Lee; Beom-Jin Lee
Journal:  Int J Nanomedicine       Date:  2022-05-17

2.  Double-Controlled Release of Poorly Water-Soluble Paliperidone Palmitate from Self-Assembled Albumin-Oleic Acid Nanoparticles in PLGA in situ Forming Implant.

Authors:  Yongjun Yu; Hai V Ngo; Gang Jin; Phuong H L Tran; Thao T D Tran; Van Hong Nguyen; Chulhun Park; Beom-Jin Lee
Journal:  Int J Nanomedicine       Date:  2021-04-13

3.  Prostate-specific membrane antigen targeted, glutathione-sensitive nanoparticles loaded with docetaxel and enzalutamide for the delivery to prostate cancer.

Authors:  Yang Chen; Zhenyu Xu; Tingxun Lu; Jia Luo; Hua Xue
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.819

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.